OncoMatch/Clinical Trials/NCT07169994
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Is NCT07169994 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including YL202 for and YL202 for for advanced solid tumors.
Treatment: YL202 for · YL202 for — This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: HER3-targeted therapy
With prior drug therapy targeting HER3 (including antibodies, antibody-drug conjugates [ADCs]), chimeric antigen receptor T-cell immunotherapy (CAR-T), and other drugs
Cannot have received: CAR-T cell therapy
With prior drug therapy targeting HER3 (including antibodies, antibody-drug conjugates [ADCs]), chimeric antigen receptor T-cell immunotherapy (CAR-T), and other drugs
Cannot have received: topoisomerase I inhibitor
Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors
Cannot have received: antibody-drug conjugate
Previously intolerant to topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors
Cannot have received: allogeneic bone marrow transplantation
Prior treatment with allogeneic bone marrow transplantation or solid organ transplantation
Cannot have received: solid organ transplantation
Prior treatment with allogeneic bone marrow transplantation or solid organ transplantation
Lab requirements
Blood counts
Adequate organ and bone marrow function.
Kidney function
Adequate organ and bone marrow function.
Liver function
Adequate organ and bone marrow function.
Adequate organ and bone marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07169994 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior HER3-targeted therapy, CAR-T cell therapy, topoisomerase I inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify